Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Biond Biologics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,125.0 million","upfrontCash":"$125.0 million","newsHeadline":"Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Deep Insight","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biond Biologics Announces Closing of $15 Million Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biond Biologics to Present at the Raymond James LILRB\/ILT Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biond Biologics Announces First Patients Dosed with BND-22 (SAR444881) Combinations in Phase 1 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Biond Biologics

    Menu

    Biond Biologics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Biond Biologics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Biond Biologics Announces First Patients Dosed with BND-22 (SAR444881) Combinations in Phase 1 Clinical Trial

              Details:

              BND-22 (SAR444881), is a humanized IgG4, antagonist antibody targeting the ILT2 receptor in development for the treatment of solid tumors, is an inhibitory receptor expressed on both innate and adaptive immune cells that binds MHC class I molecules.

              Lead Product(s): BND-22,Pembrolizumab

              Therapeutic Area: Oncology Product Name: SAR444881

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 23, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Biond Biologics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Biond Biologics to Present at the Raymond James LILRB/ILT Symposium

              Details:

              BND-22 (SAR444881), a novel immune checkpoint inhibitor targeting the Immunoglobulin-like transcript receptor 2 or ILT2, enhances anti-tumor activity of T cells and NK cells.

              Lead Product(s): BND-22,Pembrolizumab,Cetuximab

              Therapeutic Area: Oncology Product Name: BND-22

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Sanofi

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 20, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Biond Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Biond Biologics Announces Closing of $15 Million Series C Financing

              Details:

              The financing has sopported the development of BND-22 (SAR444881), the company’s Ig-Like Transcript 2 (ILT2) receptor-blocking antibody, and the first patient has been dosed in the first-in-human, phase 1 clinical trial of BND22.

              Lead Product(s): BND-22,Pembrolizumab

              Therapeutic Area: Oncology Product Name: SAR444881

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Deep Insight

              Deal Size: $15.0 million Upfront Cash: Undisclosed

              Deal Type: Series C Financing November 03, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Biond Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor

              Details:

              BND-22 is a humanized IgG4, antagonist antibody targeting the Ig-like transcript 2 (ILT2) receptor in development for the treatment of solid tumors.

              Lead Product(s): BND-22

              Therapeutic Area: Oncology Product Name: BND-22

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Sanofi

              Deal Size: $1,125.0 million Upfront Cash: $125.0 million

              Deal Type: Licensing Agreement January 12, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY